ENTITY – Page 4

Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound

5 days ago talkbio0Tagged Biopharma, eli lilly, GLP-1/GIP receptor agonist, Hansoh Pharmaceuticals, HS-20094, Licensing Deal, Obesity, Regeneron, Zepbound

Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus

6 days ago talkbio0Tagged Acquisition, Ayvakit, Biopharma, Blueprint Medicines, elenestinib, Immunology, Infrequent, Mastocytosis, Systemic, pipeline, sanofi

Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations

6 days ago talkbio0Tagged age restriction, Approved, conditions, COVID19 (disease), Effectiveness, mNEXSPIKE, Moderna, mRNA-1283, next-generation vaccine, respiratory virus season, United States Food and Drug Administration, Vaccines

Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Precision Medicine’s Next Frontier: Unlocking the Power of Biospecimens

6 days ago talkbio0Tagged biobanking, Biological Markers, biospecimens, Cancer Genomics, Drug Development, Multiomics, Precision Medicine, spatial transcriptomics

precision medicine; biospecimens; multi-omics; drug development; biobanking; personalized medicine; biomarkers; spatial transcriptomics; cancer genomics

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

6 days ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

AstraZeneca Details Its Oral SERD ‘Switching’ Regimen Amid Feasibility Questions

1 week ago talkbio0Tagged AstraZeneca, camizestrant, CDK4/6 inhibitor, Disease Progression, ESR1 gene, Malignant neoplasm of breast, Mutation, Oral SERD, SERENA-6 trial, treatment resistance

AstraZeneca; oral SERD; camizestrant; breast cancer; ESR1 mutation; SERENA-6 trial; CDK4/6 inhibitor; disease progression; ASCO 2025; treatment resistance

Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences

1 week ago talkbio0Tagged Antibody-Drug Conjugates, Astellas, Evopoint Biosciences, Licensing Deal, Neoplasms, therapeutic autologous dendritic cells

Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

1 week ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025